MedTrace Logo

Triple Therapy in Chronic Obstructive Pulmonary Disease (COPD) Participants

NCT04657211 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1212

Last updated 2025-08-17

Study results available
· View outcomes & findings →

Summary

TETRIS is a multi-center, prospective observational cohort study. It will include participants with COPD who are on an existing combined treatment of long-acting muscarinic antagonist (LAMA), long-acting beta 2 agonists (LABA) and inhaled corticosteroids (ICS).

Conditions

  • Pulmonary Disease, Chronic Obstructive

Interventions

OTHER

Prospective observational cohort study

prospective observational cohort study

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-14
Primary Completion
2024-07-01
Completion
2024-07-01

Countries

  • Germany

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04657211 on ClinicalTrials.gov